Henry McCusker's  Instablog

Henry McCusker
Send Message
Analyst, Journalist and Publisher ... Henry enters his tenth (10) year at Scimitar Equity -Regenerative Medicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • Geron (GERN) Versus BioTime (NYSE MKT: BTX),  0 comments
    Oct 19, 2012 9:03 AM

    GERN acknowledged the public release by BTX of a letter to Geron's stockholders regarding stem cell assets.

    Geron's Board of Directors has, since the announcement that Geron would be discontinuing its stem cell research and development programs, considered a number of alternatives with respect to such programs.Consistent with its fiduciary duties and responsibilities, and in consultation with its financial and legal advisors, Geron's Board of Directors will diligently review BioTime's proposal and act in a manner that the Board believes is in the best interests of Geron's stockholders. Stifel Nicolaus Weisel is acting as financial advisor and Weil, Gotshal & Manges LLP is acting as legal counsel to Geron in connection with the divestiture of Geron's stem cell assets.

    The Bottom line: It is a beginning … the war of paper flying … with lawyers flapping their arms for air support.

    Geron (NASDAQ:GERN) may have finally found a buyer for its suspended stem cell program. The company has been searching since 11/11 when Geron halted the projects to focus on the development of Imetelstat and GRN-1005, both cancer treatments. BTX) has offered to combine some of its own stem cell assets with those of Geron - plus stock in 2 BTX subsidiaries - in a new, publicly traded company, BioTime Acquisition Corp (NYSE:BAC). Through the transaction, GERN shareholders will be given a 21.4% stake in the new company (aggregate); subscription rights to purchase additional stock in BAC, potentially increasing aggregate ownership to 45%; $13 M (current value) in BTX warrants; and additional BAC warrants as part of the subscription rights. (PropThink) Through the transaction, GERN shareholders have the opportunity to continue investing in GERN's human embryonic stem cell treatments, which many are calling the future of biotech. Divesting of the stem cell program has been a high priority for GERN, and management expected it to generate capital for the company; the all-stock transaction offered by BioTime, however, will do little for Geron's balance sheet.

    GERN was up to 1.52 <from $1.42>at the close while BTX closed at $3.97 <down from $3.99>.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.